azd3241
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00729443)
Timeline
Indications
Mechanism of action
- MyeloperoxidaseINHIBITOR
MPO inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd3241
- azd3241
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02388295 | Phase 2 | Apr 1, 2015 | AstraZeneca |
| NCT01603069 | Phase 2 | Oct 1, 2012 | AstraZeneca |
| NCT01527695 | Phase 2 | Apr 1, 2012 | AstraZeneca, Karolinska Institute |
| NCT01457807 | Phase 1 | Nov 1, 2011 | AstraZeneca, IQVIA |
| NCT00914303 | Phase 1 | Jun 1, 2009 | AstraZeneca, IQVIA |
| NCT00729443 | Phase 1 | Jul 1, 2008 | AstraZeneca |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2008 |
| IQVIA | For profit | 2 | 0 | 1 | 2009 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1